Novartis cuts 183 NJ jobs; Pfizer completes Ferrosan Consumer Health buyout;

@FiercePharma: Guess this was inevitable: Senators start poking around in Pfizer's Lipitor-at-generic-price deals - NYT. Article | Follow @FiercePharma

> Novartis ($NVS) is cutting 183 jobs in New Jersey as part of its ongoing restructuring of clinical development work. News

> Pfizer ($PFE) has wrapped up its acquisition of Ferrosan Consumer Health, the Danish company that sells skincare products and dietary supplements in Russia, Europe and the Nordic countries. Story

> GlaxoSmithKline's ($GSK) new definition of core earnings, which brings it into line with its Big Pharma peers, could give the company a lift, Reuters says. Article

> Eli Lilly ($LLY) spent $2.3 million lobbying the U.S. government during the third quarter, focusing on patent reform, trade and hospital discounts. News

> Russian drugmakers are appealing to Prime Minister Vladimir Putin on pricing policies that prevent their raising the cost of products, despite inflation in labor, raw materials and energy. Story

> India's Vivimed Labs bought Uquifa, which makes active pharmaceutical ingredients in Spain and Mexico. Report

> Eisai ($ESALY) is set to launch a new formulation of the anti-coagulant warfarin in Japan. More

> Merck KGaA tapped Friederike Rotsch as its new head auditor and Isabel De Paoli to lead corporate strategy, both reporting to Chairman Karl-Ludwig Kley. Piece

Biotech News

@FierceBiotech: Study: MDs often asked for alternative vaccine schedules. Item | Follow@FierceBiotech

@RyanMFierce: Dutch-Belgian biotech arGEN-X (antibody discovery) bagged $37M in B round co-led by OrbiMed and Seventure PR. Release | Follow@RyanMFierce

@MaureenFierce: Novartis MS Pill Gilenya Rejected by U.K. Health-Cost Agency. Report | Follow @MaureenFierce

> MacroGenics pockets $20M in $450M deal with Servier. Report

Vaccines News

> Misconceptions stymie HIV vaccine trials. Report

> For stronger vaccines, pay attention to carbohydrates. Article

> China preps for big push into vaccine market. News

> Study: MDs often asked for alternative vaccine schedules. Item

Manufacturing News

> Police net $8 million in counterfeit drugs. News

> Ranbaxy drama shows manufacturing impact on pharma business. Report

> Fujifilm presses biosimilars ambition. Item

> GSK a step closer to becoming energy provider. News

> Analyst: Hospira manufacturing woes possibly systemic. Report

> Contamination concern rises about CMOs. News

And Finally... HIV treatment in the young is becoming more complicated, with children as young as 5 resistant to AIDS meds. Report

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.